BIAF vs LUNG vs NVCR

For growth investors, bioAffinity Technologies, Inc.

(BIAF) is the stronger pick with 269. 7% revenue growth year-over-year, versus 8. 0% for Pulmonx Corporation (LUNG). Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, NovoCure Limited (NVCR) delivered a total return of -91.

3%, compared to -99. 1% for bioAffinity Technologies, Inc. (BIAF). Over 10 years, the gap is even starker: NVCR returned +38. 5% versus BIAF's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), NovoCure Limited (NVCR) is the lower-risk stock at 2.

15β versus Pulmonx Corporation's 2. 31β — meaning LUNG is approximately 8% more volatile than NVCR relative to the S&P 500. On balance sheet safety, bioAffinity Technologies, Inc. (BIAF) carries a lower debt/equity ratio of 58% versus 104% for Pulmonx Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), bioAffinity Technologies, Inc.

(BIAF) is pulling ahead at 269. 7% versus 8. 0% for Pulmonx Corporation (LUNG). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to 7. 6% for Pulmonx Corporation. Over a 3-year CAGR, LUNG leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NovoCure Limited (NVCR) is the more profitable company, earning -20.

8% net margin versus -96. 6% for bioAffinity Technologies, Inc. — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVCR leads at -23. 5% versus -95. 6% for BIAF. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, NovoCure Limited (NVCR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

bioAffinity Technologies, Inc. (BIAF) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVCR: +38. 5%, BIAF: -99. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BIAF is a small-cap high-growth stock; LUNG is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.